Aluminum oxide surfaces and interface molecules
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12061195-B2
Publication Date
2024-08-13
Expiration Date
Abstract
A device, interface complex, diagnostic system, kit or method for use in binding analyte of interest, wherein immobilizing is on an aluminum oxide surface. An interface molecule is immobilized on the aluminum oxide surface. Attached to the interface molecule, is a cross linking agent for binding to the analyte, or a biomolecule specific to the analyte. The interface molecule includes a polypeptide having at least one carboxy rich domain providing at least 5 free carboxyl groups within a molecular volume of 2.2-25 nm3, the free carboxyl groups being provided by amino acids containing two or more carboxyl groups, through which the interface molecule is immobilized to the aluminum oxide surface. The biomolecule may be covalently attached to the interface molecule, or the biomolecule may bean engineered antibody attached to the interface molecule through an antigenic determinant or through an Fc fragment.
Core Innovation
The disclosed invention relates to a diagnostic system or a kit that detects whether binding has occurred to an analyte of interest. The system uses an aluminum oxide surface refunctionalized with an interface molecule comprising a polypeptide having at least one carboxy rich domain, and the interface molecule is capable of being immobilized to the aluminum oxide surface through the carboxy rich domain.
The carboxy rich domain provides at least 5 free carboxyl groups within a molecular volume of 2.2-25 nm3, where the free carboxyl groups are provided by amino acids containing two or more carboxyl groups. An immobilized analytical binding component is presented on the immobilized interface molecule in several formats, including a cross linking agent, a biomolecule specific to the analyte attached through one or more covalent bonds, or an engineered antibody with analyte-specific binding.
The interface molecule and the selected binding component are immobilized to the aluminum oxide surface, or provided as an interface complex for contact with the analyte prior to immobilizing to the aluminum oxide surface. When a sample to test for the analyte is contacted with the system, the presence of the analyte is detected upon binding to the cross linking agent or to the biomolecule, depending on which binding component format is present.
Claims Coverage
Independent claim clm-00001 defines a diagnostic system or kit for detecting analyte binding using an aluminum oxide surface functionalized with a carboxy rich polypeptide interface molecule that presents immobilizable free carboxyl groups within a specified molecular volume. It covers four classes of analyte-binding components: a cross linking agent, a covalently attached analyte-specific biomolecule, an engineered antibody attached via an antigenic determinant pair, and an engineered antibody attached via an Fc fragment with Fab fragments specific to the analyte, either immobilized directly or provided as an interface complex.
Aluminum oxide surface with immobilizable carboxy rich interface molecule
A diagnostic system or a kit comprising an aluminum oxide surface and an interface molecule comprising a polypeptide having at least one carboxy rich domain providing at least 5 free carboxyl groups within a molecular volume of 2.2-25 nm3, through which the interface molecule is capable of being immobilized to the aluminum oxide surface.
Cross-linking agent attached to the interface molecule
The system wherein the interface molecule has a cross linking agent attached to the interface molecule for binding to the analyte, and the analyte is detected upon binding of the analyte to the cross linking agent.
Covalently attached analyte-specific biomolecule
The system wherein the interface molecule has a biomolecule attached through one or more covalent bonds, the biomolecule being specific to the analyte, and the analyte is detected upon binding of the analyte to the biomolecule.
Engineered antibody attached via first antigenic determinant and second antigenic determinant
The system wherein the biomolecule is an engineered antibody attached through a first antigenic determinant specific to the interface molecule and having a second antigenic determinant specific to the analyte.
Engineered antibody attached via Fc fragment with Fab specific to the analyte
The system wherein the biomolecule is an engineered antibody attached through an Fc fragment and having Fab fragments specific to the analyte.
The inventive coverage centers on an aluminum oxide surface with a carboxy rich polypeptide interface molecule and multiple selectable analyte-binding component formats for detecting analyte binding.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?